Following the closing of a $70 million series A in July 2021, Xilis—the biotechnology company behind MicroOrganoSphere (MOS) technology, which generates thousands of miniature patient-derived tumors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results